Summary of Key Points Core Viewpoint - The June stock recommendations from 42 brokerage firms show a significant increase in the number of recommended stocks, with the pharmaceutical and biotechnology sector returning to the top of the industry recommendation rankings after three years, indicating a renewed market interest in cyclical industries [1][3]. Stock Recommendations - A total of 332 stocks received 457 recommendations, with 42 stocks from the ChiNext gaining 53 recommendations, 45 stocks from the STAR Market receiving 59 recommendations, and 43 Hong Kong stocks getting 62 recommendations, marking an increase of 6 and 7 stocks respectively compared to the previous month [1]. - Six stocks received recommendations from five brokerage firms: China Merchants Bank, Yara International, Smoore International, SF Holding, Qingdao Beer, and Haida Group [1]. - Six stocks received recommendations from four brokerage firms: Zijin Mining, China Mobile, Zhenhua Heavy Industries, Tencent Holdings, Hangzhou Bank, and Dongpeng Beverage [1]. Industry Rankings - The pharmaceutical and biotechnology sector achieved a recommendation rate of 10.2%, reclaiming the top position, while the electronics sector fell to second place with a recommendation rate of 9.3% [3]. - The food and beverage sector ranked third with a recommendation rate of 6.58%, and the machinery equipment sector ranked fourth with a rate of 6.35% [3]. - The coal industry saw a significant increase in recommendation rate by 59.6%, while the transportation sector increased by 52.1%, indicating a positive outlook for these industries [3]. Declining Industry Interest - The retail trade sector experienced a notable decline in recommendation rate by 43.17%, attributed to renewed trade tensions and previous excessive price increases [4]. - The defense and military industry saw a decrease of 34.77%, mainly due to the easing of the Russia-Ukraine situation [4]. - The automotive sector's recommendation rate dropped by 30.99%, reflecting concerns over industry competition [4]. Performance of Brokerage Recommendations - In May, 30 out of 45 brokerage firms reported positive returns, with the top performers being Guoyuan Securities (6.28%) and Caitong Securities (5.93%) [5][6]. - As of May 30, 36 out of 45 brokerage firms had positive returns for the year, with 16 firms achieving returns close to or exceeding 10% [6]. Market Outlook - Analysts suggest that June will see continued improvement in returns and win rates, with a focus on large-cap growth stocks, although the market is expected to remain volatile [7]. - The market sentiment has been affected by fluctuating U.S. tariff policies and slow progress in U.S.-China trade negotiations, which are key factors influencing market risk appetite [7].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

Core Viewpoint - The article discusses the structural differentiation in the current stock market, highlighting the significant performance gap between A-shares and Hong Kong stocks, driven by foreign capital inflow, the weight advantage of technology stocks, and differing policy expectations [2][3]. A-share High Dividend Portfolio: Stable Foundation for Value Reassessment - Financial Performance and Dividend Capability: In a low-interest and volatile market, high-dividend companies are preferred for their stable cash flow and shareholder returns. The total dividend of central state-owned enterprises is expected to reach 1.17 trillion yuan in 2024, accounting for 50% of the total A-share dividends [4][5]. - Key Companies: China Shenhua is expected to have a dividend yield of over 5.9% in 2024, while Huaneng International plans a dividend payout ratio of at least 50% of distributable profits. Wuliangye and Muyuan Foods are also highlighted for their strong financial performance and dividend potential [4][5][6]. - Competitive Moat: The sustainability of the high-dividend portfolio relies on the companies' competitive advantages, including cost advantages in the energy sector and brand differentiation in consumer goods [6]. - Market Outlook: The core opportunities for the high-dividend portfolio in 2025 include the resonance of declining interest rates and stable growth policies, with specific catalysts in the energy and consumer sectors [7]. Hong Kong Growth Portfolio: Profit Elasticity and Industry Wave Resonance - Financial Performance and Growth Momentum: The Hong Kong portfolio focuses on internet, consumer, and innovative pharmaceutical sectors, benefiting from global liquidity easing and AI breakthroughs. Meituan's revenue is expected to reach 337.6 billion yuan in 2024, with a net profit increase of 158.4% [8][9]. - Competitive Moat: The growth portfolio's moat is derived from network effects, research and development accumulation, and global capabilities, with companies like Tencent and Meituan leveraging their ecosystems [10]. - Market Outlook: The core opportunities for the Hong Kong growth portfolio in 2025 are driven by global liquidity easing and clear industry policy catalysts, particularly in AI applications and innovative pharmaceuticals [11]. Comparison of Portfolios and Investor Preferences - Market Performance and Fund Flows: Investors are currently favoring the Hong Kong growth portfolio due to significant performance differences, with the Hang Seng Index rising 16.1% compared to the -2.41% decline of the CSI 300 [13][14]. - Investor Structure Preference: The high-dividend portfolio attracts conservative investors such as insurance funds, while the growth portfolio appeals to foreign capital and growth-oriented funds [15][16]. - Current Popularity Assessment: The Hong Kong growth portfolio is more favored due to its higher earnings growth rate and alignment with global technology trends, while the high-dividend portfolio remains attractive for risk-averse investors [16][17].

Core Insights - The ASCO conference has witnessed the rise of Chinese innovative drugs, with a significant increase in the number of oral presentations and Late-Breaking Abstracts from Chinese researchers over the past decade [1][2][4] - Chinese biopharmaceutical companies are now recognized for their quality research, with many studies presenting groundbreaking results that have global implications [4][5] - The "ASCO effect" has begun to influence stock prices of Chinese pharmaceutical companies, reflecting the growing importance of their research in the global market [5][6] Company Highlights - China Biologic Products set a record with 12 oral presentations at ASCO 2025, including 4 Late-Breaking Abstracts, totaling over 40 studies presented [4] - Innovative studies such as the DIAMOND trial by Junshi Biosciences have demonstrated significant advancements in treatment protocols, marking a shift from merely participating to leading in global research [4] - Companies like Innovent Biologics and Hengrui Medicine are at the forefront of ADC and bispecific antibody development, with numerous studies presented at ASCO [8][12] Industry Trends - The ADC sector is dominated by Chinese companies, with 89 out of 184 ADC-related studies presented at ASCO coming from China, representing approximately 48.4% of the total [8][10] - The bispecific antibody (bispecific) pipeline from China accounts for nearly 50% of the global total, with significant clinical advancements reported at ASCO [12][14] - The trend of increasing license-out transactions and upfront payments for Chinese innovative drugs indicates a shift in the global pharmaceutical landscape, with a notable rise in the use of the NewCo model for collaborations [18][24] Market Impact - The stock prices of companies like China Biologic Products and Innovent Biologics have seen significant increases following the ASCO conference, indicating a positive market response to their research presentations [6] - The total value of license-out transactions for Chinese pharmaceutical companies has surged, with a notable increase in upfront payments, reflecting enhanced negotiation power [20][24] - The emergence of new treatment modalities and innovative drug pipelines positions Chinese companies as key players in the global biopharmaceutical market [16][18]

Core Insights - The National Medical Products Administration approved 11 innovative drugs recently, with 10 coming from listed companies, indicating a significant advancement in China's pharmaceutical sector [1][4] - The approval of these drugs marks a pivotal moment for the industry, as it transitions into a phase of realizing the results of extensive research and development efforts [7][8] Group 1: Drug Approvals and Innovations - Among the approved drugs, several are the first of their kind in China, including Bai Jie Shen Zhou's injection of Zhenida Monoclonal Antibody, which is the first HER2 dual-target drug approved for cholangiocarcinoma [4][5] - Heng Rui Pharmaceutical's Apixaban is a multi-target tyrosine kinase inhibitor approved for use in advanced solid tumors, showcasing innovative treatment mechanisms [4][5] - The approval of Zai Jing Pharmaceutical's Jikaxitinib marks the first domestic JAK inhibitor for treating myelofibrosis, providing new options for patients with rare blood cancers [5][6] Group 2: Market Trends and Investment Opportunities - The innovative drug sector has seen a strong market performance, with 53 stocks hitting the daily limit up, indicating heightened investor interest [2][7] - Analysts predict that 2025 will be a transformative year for the pharmaceutical industry, characterized by increased revenue, profitability, and valuation improvements [1][7] - The Hong Kong innovation drug index has seen significant capital inflow, with over 200 million yuan in net inflow over the past 20 trading days, reflecting strong market sentiment [2][8] Group 3: Challenges and Future Outlook - Despite the positive developments, the innovative drug industry faces challenges such as high uncertainty in commercialization and intense competition among similar products [7][8] - The industry is supported by favorable policies and the growth of commercial health insurance, which enhances the payment environment for innovative drugs [8]

Core Insights - Baiyue Shenzhou's bispecific HER2 inhibitor, Zhenidamab (百赫安), received conditional approval from the National Medical Products Administration (NMPA) for treating HER2-positive advanced or metastatic biliary tract cancer (BTC) patients who have previously undergone systemic therapy [1][2] - This approval marks Zhenidamab as the first and only bispecific antibody approved in China for targeted therapy of HER2-positive biliary cancer, providing a new treatment option for patients [1][2] - The incidence of biliary tract cancer is on the rise, with approximately 15% to 30% of BTC patients exhibiting HER2 abnormalities, making HER2 a key target for BTC treatment [1] Clinical Data - The conditional approval is based on the results of the global multicenter clinical study HERIZON-BTC-01, which showed an objective response rate (ORR) of 51.6% in previously treated, unresectable HER2-positive advanced or metastatic BTC patients [2] - The median duration of response (mDoR) was 14.9 months, and the median overall survival (mOS) was 18.1 months, indicating a significant improvement in survival compared to previous second-line chemotherapy options [2] - The safety profile of Zhenidamab was reported to be favorable, demonstrating good overall safety [2] Mechanism of Action - Zhenidamab utilizes a dual-targeting mechanism by binding to two different non-overlapping epitopes of the HER2 protein, enhancing its binding and inhibitory capabilities, which may lead to a synergistic effect in tumor suppression [2] - This innovative mechanism allows for dual signal blockade and the formation of larger receptor clusters, potentially improving therapeutic efficacy [2] Strategic Collaboration - Zhenidamab was developed by Zymeworks, with Baiyue Shenzhou entering a strategic partnership for its development and commercialization in Asia (excluding Japan), Australia, and New Zealand [3] - The drug is also set to be available in the United States, having received FDA approval for the same indication in November 2024 [3] - The President and COO of Baiyue Shenzhou expressed confidence that this innovative drug will significantly benefit the survival of BTC patients in China [3]

Core Viewpoint - The article discusses the performance and holdings of the ICBC Frontier Medical Stock C fund, highlighting its recent growth and ranking among similar funds [1]. Fund Performance - The latest net value of ICBC Frontier Medical Stock C is 2.9850 yuan, reflecting a growth of 3.36% [1]. - The fund's return over the past month is 5.06%, ranking 72 out of 1022 similar funds [1]. - Over the last three months, the return is 10.06%, with a ranking of 63 out of 1009 [1]. - Year-to-date, the fund has achieved a return of 12.46%, ranking 107 out of 999 [1]. Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05% of the fund, with the following key positions: - Heng Rui Medicine: 10.11% - Kelun Pharmaceutical: 8.01% - WuXi AppTec: 7.72% - BeiGene: 6.85% - Xinlitai: 4.90% - Zai Lab: 4.77% - Yuyue Medical: 4.60% - New Horizon: 4.36% - East China Pharmaceutical: 4.20% - Haizhi Pharmaceutical: 3.53% [1]. Fund Background - ICBC Frontier Medical Stock C was established on November 23, 2020, and as of March 31, 2025, it has a total scale of 1.38 billion yuan [1]. - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2].

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

作者 | 黄绎达 编辑 | 郑怀舟 在A股市场，鲜有连续熊市超过三年的行业板块，而医药板块是其中的典型。从2021年7月到去年924行情启动之前，该板块经历了连续3年的下行调整， 申万医药生物指数在此期间的跌幅高达54%，板块市值近乎腰斩，众多医药龙头股亦同步陷入估值与业绩的双重回调。 在医药板块持续低迷的周期中，曾经风光无两的医药主题基金（以下简称：医药基金）也褪去了往日的光彩。根据wind统计，受医药板块长期熊市的拖 累，即便有去年924行情的提振，今年医药板块有所反弹，目前存续的600余只医药基金中，截至今年5月28日，大约2/3的基金净值目前还在1以下，最低 者甚至只有0.35。 但是从短期来看，进入2025年后，半数以上的医药基金在今年（截至5月28日）取得了正收益，表现优异者如长城医药产业精选、永赢医药创新智选、华 安医药生物、中银大健康等基金的同期收益在47%~56%区间，同类基金同期排名亦均位于前列，似乎医药基金的春天回来了。 那么，驱动医药基金在今年回暖的核心因素都有哪些？医药基金现在还能买吗？ 01 医药大盘反弹在beta层面支撑医药基金走强 医药基金近年来长期表现相对颓势，在不发生风格漂 ...

Core Insights - The approval of multiple BTK inhibitors in China is transforming the treatment landscape for Chronic Lymphocytic Leukemia (CLL) and B-cell lymphomas, with a notable shift towards second-generation BTK inhibitors [1][3][4] Group 1: Market Overview - As of now, five BTK inhibitors have been approved in China, including three imported drugs and two domestic drugs, with the first-generation inhibitor ibrutinib and three second-generation inhibitors [3] - The global incidence of CLL is significant, with 191,000 new cases and 61,000 deaths annually, primarily affecting elderly patients with a median age of 65 in China [2] Group 2: Treatment Efficacy and Safety - The five-year survival rate for CLL patients is high, ranging from 80% to 90%, with low-risk patients having a median survival of nearly 20 years [2] - Newer BTK inhibitors demonstrate improved safety profiles compared to first-generation inhibitors, which have seen a decline in global recommendation levels due to safety concerns [3][4] Group 3: Future Directions - The development of BCL2 inhibitors is underway, with ongoing clinical trials combining these with BTK inhibitors, indicating a potential new direction for CLL treatment [5] - The increasing elderly population in China presents challenges for long-term management of CLL patients, necessitating systematic approaches to address treatment adherence and adverse effects [5]